These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 27633469)
1. Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist. Simpson JD; Matthews GV; Brighton TA; Joseph JE Intern Med J; 2016 Sep; 46(9):1096-9. PubMed ID: 27633469 [TBL] [Abstract][Full Text] [Related]
2. Eltrombopag for chronic immune thrombocytopenia. Tanimoto T; Fukunaga S; Hori A; Yagasaki F; Ono S Lancet; 2011 Jun; 377(9781):1919; author reply 1919-20. PubMed ID: 21641478 [No Abstract] [Full Text] [Related]
3. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038 [TBL] [Abstract][Full Text] [Related]
4. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series. Kowalczyk M; Rubinstein PG; Aboulafia DM J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472 [TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma. Ferretti A; Baldacci E; Miulli E; Canichella M; Di Rocco A; Pulsoni A; Martelli M; Serrao A; Chistolini A; Gabriella Mazzucconi M; Foà R; Santoro C Br J Haematol; 2019 Sep; 186(6):e217-e219. PubMed ID: 31364154 [No Abstract] [Full Text] [Related]
6. Eltrombopag in systemic lupus erythematosus with antiphospholipid syndrome: thrombotic events. Boulon C; Vircoulon M; Constans J Lupus; 2016 Mar; 25(3):331. PubMed ID: 26405023 [No Abstract] [Full Text] [Related]
8. Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center. Suntsova EV; Maschan AA; Baydildina DD; Kalinina II; Petrova UN; Pshonkin AV; Novichkova GA Pediatr Blood Cancer; 2019 Jun; 66(6):e27704. PubMed ID: 30854783 [TBL] [Abstract][Full Text] [Related]
9. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736 [No Abstract] [Full Text] [Related]
10. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review. Depré F; Aboud N; Mayer B; Salama A Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387 [TBL] [Abstract][Full Text] [Related]
11. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630 [TBL] [Abstract][Full Text] [Related]
16. Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia. Qu MM; Liu XN; Liu XG; Feng Q; Liu Y; Zhang X; Liu S; Zhang L; Li GS; Zhu YY; Lv MY; Peng J; Hou M Cytokine; 2017 Apr; 92():110-117. PubMed ID: 28142109 [TBL] [Abstract][Full Text] [Related]
17. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191 [No Abstract] [Full Text] [Related]